Odicrain to Present at Medtech Insight's ``In Circulation'' Conference.
--Odicrain has announced that it will be presenting at 3:10 pm at Medtech Insight's Prestigious "In Circulation: Strategic Partnering and Investing in Circulatory Medicine" Conference, taking place April 27, 2005 at the Hyatt Regency McCormick Place in Chicago, IL.
Odicrain introduces Crainscan, a portable device for rapid and mobile detection of intracranial hematoma. After market entry of this product in non-US markets, Odicrain is planning to start regulatory approval and market launch in the US in 2005.
An important application for this device is the differentiation between brain infarction (approximately 85% of all strokes) and an hemorrhagic stroke (approximately 15% of all strokes). Time is the most important factor for outcome at brain injured patients. The sooner a correct diagnosis can be made and the sooner "brain saving" therapy can be initiated, the better the patients outcome and chance to survive will be.
Patients with brain infarctions can be treated by rtPA therapy. But by treating a patient with intracranial bleedings unknowingly by such a therapy, the patient would experience a life threatening situation. Therefore rtPA therapy is usually only then started, when an exact diagnosis by computer-tomography is made. But until such diagnosis is completed, a quite significant period of time may be gone. By an earlier diagnosis, apoplexy patients can be diagnosed already in a very early phase at the initial point of care and treatment of such patients by "brain saving" medication can start much sooner. This will improve the patients outcome significantly and will reduce the number of disabled patients.
Another application within stroke is the monitoring of brain infarction patients treated by rtPA therapy. Many of these patients are experiencing bleedings during the treatment. Such hematoma may be diagnosed by Crainscan in an already early phase within a routine check at the patients bed side. Also here the bleedings can be treated much sooner, which again will improve the patients outcome.
Beside stroke, Crainscan is applied at patients with traumatic brain injuries. For both applications, stroke and trauma patients, studies showed the clinical relevance of Crainscan to detect this pathologies earlier. For both applications, Crainscan represents a quite significant market potential.
Based on near-infrared spectroscopy technology, Crainscan is measuring the optical density of tissue. The optical density is changed significantly in the presence of intracranial bleedings. Based on this principle, the small and portable device is able to detect intracranial bleedings at any place, wherever an emergency situation may arise.
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "In Circulation" conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail email@example.com, or visit www.medtechinsight.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 18, 2005|
|Previous Article:||Vital Sensors to Present at Medtech Insight's ``In Circulation'' Conference.|
|Next Article:||Dolby Digital Plus and MLP Lossless Selected as Optional Audio Codecs by the Blu-ray Disc Association.|